Trial · NCT03541174
Participant flow66
How many started, completed or left each group, period by period.
41 to 60 of 66
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 2 Single-Blind | NOT COMPLETED | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | 0 | |
| Part 2 Single-Blind | NOT COMPLETED | Placebo in Part 3 (Double-blind Withdrawal) | 0 | |
| Part 3 Double-Blind Withdrawal | STARTED | Aprocitentan 12.5 mg in Part 1 (Double-blind) | 0 | |
| Part 3 Double-Blind Withdrawal | STARTED | Aprocitentan 25 mg in Part 1 (Double-blind) | 0 | |
| Part 3 Double-Blind Withdrawal | STARTED | Placebo in Part 1 (Double-blind) | 0 | |
| Part 3 Double-Blind Withdrawal | STARTED | Aprocitentan 25 mg in Part 2 (Single-blind) | 0 | |
| Part 3 Double-Blind Withdrawal | STARTED | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | 307 | |
| Part 3 Double-Blind Withdrawal | STARTED | Placebo in Part 3 (Double-blind Withdrawal) | 307 | |
| Part 3 Double-Blind Withdrawal | Safety Set | Aprocitentan 12.5 mg in Part 1 (Double-blind) | 0 | |
| Part 3 Double-Blind Withdrawal | Safety Set | Aprocitentan 25 mg in Part 1 (Double-blind) | 0 | |
| Part 3 Double-Blind Withdrawal | Safety Set | Placebo in Part 1 (Double-blind) | 0 | |
| Part 3 Double-Blind Withdrawal | Safety Set | Aprocitentan 25 mg in Part 2 (Single-blind) | 0 | |
| Part 3 Double-Blind Withdrawal | Safety Set | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | 310 | |
| Part 3 Double-Blind Withdrawal | Safety Set | Placebo in Part 3 (Double-blind Withdrawal) | 303 | |
| Part 3 Double-Blind Withdrawal | COMPLETED | Aprocitentan 12.5 mg in Part 1 (Double-blind) | 0 | |
| Part 3 Double-Blind Withdrawal | COMPLETED | Aprocitentan 25 mg in Part 1 (Double-blind) | 0 | |
| Part 3 Double-Blind Withdrawal | COMPLETED | Placebo in Part 1 (Double-blind) | 0 | |
| Part 3 Double-Blind Withdrawal | COMPLETED | Aprocitentan 25 mg in Part 2 (Single-blind) | 0 | |
| Part 3 Double-Blind Withdrawal | COMPLETED | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | 288 | |
| Part 3 Double-Blind Withdrawal | COMPLETED | Placebo in Part 3 (Double-blind Withdrawal) | 289 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03541174/flow?page=3